Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Effectiveness and Safety of ER OROS Paliperidone in Patients With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have given their own consent in writing to participate in the study~* Patients diagnosed with schizophrenia according to the diagnostic criteria of DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 295.30, 295.10, 295.20, 295.90, 295.60)~* Patients who have acute symptoms of schizophrenia~* Both inpatients and outpatients are acceptable~Exclusion Criteria:~* A DSM-IV (Diagnostic and Statistical Manual of Mental Disorders) of a mental disease diagnosis other than schizophrenia~* A DSM-IV diagnosis of substance-related disorder (except nicotine dependence and caffeine dependence) within 180 days before the screening test~* Total PANSS (Positive and Negative Syndrome System) score at the screening test \<70 or \>120~* Patients treated with three or more types of antipsychotic within 28 days before the screening test~* Parkinson's disease (except for those with drug-induced extra pyramidal symptoms)~* Patients with a complication of or a past history of cerebrovascular accident~* Patients with a complication of or a past history of diabetes mellitus

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ER OROS paliperidone (Type: EXPERIMENTAL): Extended Release (ER) Osmotic Controlled-Release Oral Delivery System (OROS) paliperidone
- Placebo (Type: PLACEBO_COMPARATOR): None
- Olanzapine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).